These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16886139)

  • 1. [Reimbursement of drug expenses--unseen problem, increasing threats].
    Lukawiecki K
    Kardiol Pol; 2006 Jul; 64(7):767-9; discussion 770. PubMed ID: 16886139
    [No Abstract]   [Full Text] [Related]  

  • 2. [Changes of drug reimbursement expenses incurred by National Health Fund in Silesian voivodeship in the period of 1999-2004].
    Swistak P; Dzielicki M; Janiec R; Błońska-Fajfrowska B
    Wiad Lek; 2005; 58(9-10):495-9. PubMed ID: 16529058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06.
    O'Reilly DJ; Goeree RA; Tarride JE; James C; Parfrey PS
    Can J Clin Pharmacol; 2009; 16(2):e346-59. PubMed ID: 19531813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacy benefit and transaction-based reimbursement.
    Cole DL
    Med Interface; 1995 Apr; 8(4):56-7. PubMed ID: 10141766
    [No Abstract]   [Full Text] [Related]  

  • 5. Perspective. Senior drug use unique, needs management, analysts say.
    Med Health; 2001 Aug; 55(30):7-8. PubMed ID: 11507947
    [No Abstract]   [Full Text] [Related]  

  • 6. Four-dollar generics--increased accessibility, impaired quality assurance.
    Choudhry NK; Shrank WH
    N Engl J Med; 2010 Nov; 363(20):1885-7. PubMed ID: 21067379
    [No Abstract]   [Full Text] [Related]  

  • 7. Datawatch. Rx coverage and consumer ads: a costly combo.
    Bus Health; 1998 Oct; 16(10):68. PubMed ID: 10185119
    [No Abstract]   [Full Text] [Related]  

  • 8. Potent statin goes generic.
    Johns Hopkins Med Lett Health After 50; 2006 Dec; 18(10):7. PubMed ID: 17290530
    [No Abstract]   [Full Text] [Related]  

  • 9. Prescription benefit design: perspectives, reimbursement issues, and future trends.
    Owens G; Balfour D; Cohen J; Cohen S; Jacobs M; Lease M; Ratnesar R; Schaecher KL; Wilcox DE
    Am J Manag Care; 2004 Oct; 10(13 Suppl):S420-3. PubMed ID: 15622873
    [No Abstract]   [Full Text] [Related]  

  • 10. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
    Kong Y
    Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canada's New Generic Pricing Policy: A Reasoned Approach to a Challenging Problem.
    Hollis A; Grootendorst P
    Healthc Policy; 2015 Aug; 11(1):10-4. PubMed ID: 26571465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International prices and availability of pharmaceuticals in 2005.
    Danzon PM; Furukawa MF
    Health Aff (Millwood); 2008; 27(1):221-33. PubMed ID: 18180499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlling prescription drug expenditures: a report of success.
    Miller DP; Furberg CD; Small RH; Millman FM; Ambrosius WT; Harshbarger JS; Ohl CA
    Am J Manag Care; 2007 Aug; 13(8):473-80. PubMed ID: 17685828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic aspects of the new Spanish laws on pharmaceutical preparations.
    Antoñanzas F; Oliva J; Pinillos M; Juàrez C
    Eur J Health Econ; 2007 Sep; 8(3):297-300. PubMed ID: 17401592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing generic drug use in Medicare Part D: the role of government.
    Kohl H; Shrank WH
    J Am Geriatr Soc; 2007 Jul; 55(7):1106-9. PubMed ID: 17608887
    [No Abstract]   [Full Text] [Related]  

  • 16. The stratification of drug expenditures incurred by Poles.
    Swistak P; Wikiński M; Swistak J; Błonska-Fajfrowska B
    Wiad Lek; 2007; 60(9-10):429-32. PubMed ID: 18350716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Policies concerning pharmaceutical prices and reimbursement in Mexico, Organization for Co-operation and Economic Development. 2007].
    Moïse P; Docteur E
    Salud Publica Mex; 2008; 50 Suppl 4():S504-10. PubMed ID: 19082262
    [No Abstract]   [Full Text] [Related]  

  • 18. Medicaid drug system, AWP policies are 'broken'.
    Med Health; 2005 Jul; 59(23):4. PubMed ID: 16104107
    [No Abstract]   [Full Text] [Related]  

  • 19. Physicians' opinions and experiences of the Pharmaceutical Benefits Reform.
    Andersson K; Jörgensen T; Carlsten A
    Scand J Public Health; 2006; 34(6):654-9. PubMed ID: 17132599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy: what's the problem with generic antiepileptic drugs? A call to action.
    Miller JW; Anderson GD; Doherty MJ; Poolos NP
    Neurology; 2007 Oct; 69(18):1806-8. PubMed ID: 17967998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.